REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 12
08/03/2016 12:10
- Part 12: For the preceding part double click ID:nRSH4027Rk
governments and healthcare authorities, the outcome of negotiations with
third party payers, erosion of IP rights, including infringement by third
parties, failure to show a differentiated product profile and changes in
prescribing habits.As a result, we cannot be certain that compounds
currently under development will achieve success, and our ability to
accurately assess, prior to launch, the eventual efficacy or safety of a
new product once in broader clinical use can only be based on data
available at that time, which is inherently limited due to relatively
short periods of product testing and relatively small clinical study
patient samples. The commercialisation of biologics is often more complex
than for small molecule pharmaceutical products, primarily due to
differences in the mode of administration, technical aspects of the
- More to follow, for following part double click ID:nRSH4027RmRecent news on AstraZeneca
See all newsRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Enhertu improved IDFS in early BC in DB-05
Announcement